-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

296 Mechanical Thromboprophylaxis and Hospital-Acquired Venous Thromboembolism: A Report from the Children’s Healthcare Advances in Thrombosis Consortium

Program: Oral and Poster Abstracts
Type: Oral
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis in Pregnancy and Childhood
Hematology Disease Topics & Pathways:
Research, Anticoagulant Drugs, Epidemiology, Clinical Research, Health outcomes research, Pediatric, Devices, Treatment Considerations, Non-Biological therapies, Study Population, Human
Saturday, December 7, 2024: 4:15 PM

Nikhil Vallabhaneni, DO1*, Marisol Betensky, MD, MPH2,3, Amy Stillings, BS, CCRP4*, Emily Krava, MPH4*, Julie Jaffray, MD, MS5, Brian R. Branchford, MD6, Maua Mosha, MPH7*, Dina Ashour, MPH3*, Neil Goldenberg, MD, PhD8 and Anthony A Sochet, MD, MSc9,10*

1Medical College of Georgia, Augusta
2Johns Hopkins University School of Medicine, Baltimore, MD
3Johns Hopkins All Children's Hospital, Saint Petersburg, FL
4University of California, San Diego, San Diego, CA
5Rady Children's Hospital San Diego, San Diego, CA
6Versiti Medical Sciences Institute, Wauwatosa, WI
7Data Coordinating Center for Pediatric Multicenter Studies, Johns Hopkins All Children’s Hospital Institute for Clinical and Translational Research, St. Petersburg, FL
8Johns Hopkins All Children's Hospital, St. Petersburg, FL
9Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St. Petersburg, FL
10Anesthesiology and Critical Care Medicine, John Hopkins University School of Medicine, Baltimore, MD

Background: Mechanical thromboprophylaxis (mTP) is applied to critically ill children without trial-derived or observational evidence to suggest a risk reduction for hospital-acquired venous thromboembolism (HA-VTE).

Aims: To assess potential associations between mTP and HA-VTE among critically ill adolescents.

Methods: We performed a multicenter case-control study as a secondary analysis of the Childrens Healthcare Advances in Thrombosis (CHAT) Consortium registry including children 12-19 years of age admitted to a CHAT participating pediatric intensive care unit (PICU). Cases with HA-VTE, defined as radiographically confirmed pulmonary embolism and/or limb/neck/abdominal deep venous thrombosis (DVT) excluding those present on admission, and controls without HA-VTE were identified for study. The primary exposure variable of interest was mTP administration. Data collected for analysis included demographics, body mass index, HA-VTE characteristics, pharmacologic TP (pTP) and mTP use, central venous catheterization (CVC), invasive mechanical ventilation (IMV) use and duration, hospital length of stay (LOS), Braden Q immobility scores, and concomitant disorders such as sepsis, hematologic malignancy, congenital heart disease, and autoimmune/rheumatologic disease. To assess a priori thrombotic risk, HA-VTE risk-tiers (low, moderate, and high) were calculated based on Arlikar et al. For each tier, multivariate logistic regression models for HA-VTE were employed, reporting adjusted odds ratios (aOR) with 95% confidence intervals (CIs).

Results: A total of 163 HA-VTE cases and 975 non-HA-VTE controls were identified for study, of which 23.5% received mTP, 7.6% pTP, and 9.2% both mTP and pTP. Most HA-VTE were lower/upper extremity DVT (89%) and CVC-related (59.5%). Compared to controls, cases more frequently had CVC (89% vs 21.1%), IMV (52.2% vs 11.8%), longer median LOS (29 [IQR:15-46] vs 6 [IQR:3-10] days), complete / very limited mobility by Braden Q score (72.6% vs 22.1%), and sepsis (48.5% vs 16%) (all p<0.001). In the high HA-VTE-risk tier, a multivariate logistic regression model for HA-VTE did not detect an association with mTP (aOR: 0.49, 95%CI: 0.16-1.46, p=0.2) but did detect associations with pTP (aOR: 0.18, 95%CI: 0.04-0.78, p=0.022), combined pTP and mTP (aOR: 0.20, 95%CI: 0.06-0.66, p=0.008), IMV >1 day (aOR: 4.25, 95%CI: 1.63-11.03, p=0.003), and complete / very limited mobility (aOR 3.72, 95%CI: 1.4-9.8, p=0.008).

Conclusions: Among critically ill adolescents at high risk for HA-VTE, pTP or the combination of pTP and mTP, but not mTP alone, was associated with a risk reduction for HA-VTE. By contrast IMV and immobility are also independently associated with increased HA-VTE risk. Taken in sum, these findings identify an important risk-stratified population for upcoming pediatric pTP clinical trials.

Disclosures: Betensky: Zoll: Honoraria; Aziyo: Honoraria; NHLBI K23: Research Funding; Boston Scientific: Honoraria; Abbot: Honoraria. Branchford: Novo Nordisk: Honoraria; Kedrion: Honoraria, Research Funding. Goldenberg: Boehringer Ingelheim: Research Funding; NHLBI K24: Research Funding; Pfizer: Consultancy; J&J: Consultancy; Chiesi: Consultancy; Bayer: Consultancy; Anthos: Consultancy.

*signifies non-member of ASH